安捷伦科技PD-L1 IHC 28-8 PharmDx检测获FDA批准，覆盖食管鳞癌、胃癌、胃食管结合部及食管腺癌

美股速递07-14

安捷伦科技宣布，其PD-L1 IHC 28-8 PharmDx检测试剂已获得美国食品药品监督管理局的批准。此次获批扩展了该检测的伴随诊断适应症，现可用于食管鳞状细胞癌、胃癌、胃食管结合部腺癌以及食管腺癌患者。这一进展意味着临床医生能够更精准地识别可能从特定免疫疗法中获益的患者群体，为上述癌症类型的个体化治疗提供了重要的辅助诊断工具。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1118126407?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-14 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118126407","market":"us","top_or_hot":-1,"title":"安捷伦科技PD-L1 IHC 28-8 PharmDx检测获FDA批准，覆盖食管鳞癌、胃癌、胃食管结合部及食管腺癌","media":"美股速递","content":"<p>安捷伦科技宣布，其PD-L1 IHC 28-8 PharmDx检测试剂已获得美国食品药品监督管理局的批准。此次获批扩展了该检测的伴随诊断适应症，现可用于食管鳞状细胞癌、胃癌、胃食管结合部腺癌以及食管腺癌患者。这一进展意味着临床医生能够更精准地识别可能从特定免疫疗法中获益的患者群体，为上述癌症类型的个体化治疗提供了重要的辅助诊断工具。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>安捷伦科技PD-L1 IHC 28-8 PharmDx检测获FDA批准，覆盖食管鳞癌、胃癌、胃食管结合部及食管腺癌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n安捷伦科技PD-L1 IHC 28-8 PharmDx检测获FDA批准，覆盖食管鳞癌、胃癌、胃食管结合部及食管腺癌\n</h2>\n\n<h4 class=\"meta\">\n\n2026-07-14 20:01 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>安捷伦科技宣布，其PD-L1 IHC 28-8 PharmDx检测试剂已获得美国食品药品监督管理局的批准。此次获批扩展了该检测的伴随诊断适应症，现可用于食管鳞状细胞癌、胃癌、胃食管结合部腺癌以及食管腺癌患者。这一进展意味着临床医生能够更精准地识别可能从特定免疫疗法中获益的患者群体，为上述癌症类型的个体化治疗提供了重要的辅助诊断工具。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BN0W2T93.GBP","symbol_name":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","start_time":0,"source_url":"","article_id":"1118126407","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118126407","pubTimestamp":1784030518,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"安捷伦科技宣布，其PD-L1 IHC 28-8 PharmDx检测试剂已获得美国食品药品监督管理局的批准。此次获批扩展了该检测的伴随诊断适应症，现可用于食管鳞状细胞癌、胃癌、胃食管结合部腺癌以及食管腺癌患者。这一进展意味着临床医生能够更精准地识别可能从特定免疫疗法中获益的患者群体，为上述癌症类型的个体化治疗提供了重要的辅助诊断工具。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","LU2092937221.SGD":"Blackrock Circular Economy A2 SGD-H","BK4121":"生命科学工具和服务","LU1721428933.USD":"法巴全球经典环境基金RH MD Dis","LU2229751404.USD":"ALLIANZ GLOBAL WATER \"AT3\" (USD) ACC","LU1721429741.USD":"BNP PARIBAS SMART FOOD \"CRH\" (USD) INC","LU0347712357.USD":"BNP PARIBAS GLOBAL ENVIRONMENT \"C\" (USD) ACC","LU2413666426.HKD":"BNP PARIBAS GLOBAL ENVIRONMENT \"C\" (HKD) ACC","A":"安捷伦科技","BK4567":"ESG概念","BK4585":"ETF&股票定投概念","LU2041044095.USD":"Blackrock Circular Economy A2 USD","LU2413666699.HKD":"BNP PARIBAS GLOBAL ENVIRONMENT \"CRH\" (HKDHDG) INC","LU1721429402.USD":"BNP PARIBAS SMART FOOD \"C\" (USD) ACC","LU1543694498.USD":"法巴水资源基金RH MD Dis","BK4588":"碎股","LU1165135440.EUR":"BNP Paribas Aqua Classic Cap EUR","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","LU2089279066.USD":"ALLIANZ GLOBAL WATER \"AT\" (USD) ACC"},"translate_title":"Agilent Technologies PD-L1 IHC 28-8 PharmDx test approved by FDA to cover esophageal squamous cell carcinoma, gastric cancer, gastroesophageal junction and esophageal adenocarcinoma","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"A":1},"content_text":"安捷伦科技宣布，其PD-L1 IHC 28-8 PharmDx检测试剂已获得美国食品药品监督管理局的批准。此次获批扩展了该检测的伴随诊断适应症，现可用于食管鳞状细胞癌、胃癌、胃食管结合部腺癌以及食管腺癌患者。这一进展意味着临床医生能够更精准地识别可能从特定免疫疗法中获益的患者群体，为上述癌症类型的个体化治疗提供了重要的辅助诊断工具。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1118126407","isCrawlerRequest":true}